Pattern of disease and response to pembrolizumab in recurrent cervical cancer

• Príomhchruthaitheoirí: Kathryn M. Miller (Údar), Olga T. Filippova (Údar), Sara A. Hayes (Údar), Nadeem R. Abu-Rustum (Údar), Carol Aghajanian (Údar), Vance Broach (Údar), Lora H. Ellenson (Údar), Pier Selenica (Údar), Elizabeth L. Jewell (Údar), Chrisann Kyi (Údar), Yuliya Lakhman (Údar), Jennifer J. Mueller (Údar), Roisin E. O'Cearbhaill (Údar), Kay J. Park (Údar), Yukio Sonoda (Údar), Dmitriy Zamarin (Údar), Britta Weigelt (Údar), Mario M. Leitao, Jr (Údar), Claire F. Friedman (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Elsevier, 2021-08-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Objective: Since the approval of pembrolizumab for advanced or recurrent PD-L1 positive (CPS > 1%) cervical cancer, the clinical characteristics associated with response have remained undefined. We sought to characterize the clinicopathologic features of patients with advanced cervical cancer at...